Novo NordiskSee all their emails

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A

A real announcement email from Novo Nordisk. Captured September 17, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk announces CHMP positive opinion recommending EU approval for FREHEMGO (denecimig) for haemophilia A.

Single-column corporate press release layout featuring a small top-left logo, bullet points, multi-paragraph text, contact tables, and legal footer.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.